Phaseline

Companies › Mural Oncology

Mural Oncology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Nemvaleukin alfa (ALKS 4230)
IL-2 receptor agonist
IL2RAPhase 1Advanced Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04592653Nemvaleukin alfa (ALKS 4230)Phase 1Advanced Solid TumorOncologyJul 2024

Targets

IL2RA (1)

Companies with the same targets

Nektar Therapeutics Regeneron Pharmaceuticals PolTREG GI Innovation Synthekine AgonOx CellTrans

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.